key: cord-0779193-1bolsya4
authors: Hagiya, Hideharu; Otsuka, Fumio
title: Ivermectin for coronavirus disease 2019: Yet to be well evaluated before clinical use
date: 2021-07-12
journal: Clin Ther
DOI: 10.1016/j.clinthera.2021.07.007
sha: 895e7a7fc20a960ce1826cbf9f9e7770a00b2262
doc_id: 779193
cord_uid: 1bolsya4

nan

randomized, double-blind clinical trial, 35 patients were treated with ivermectin, and 34 patients were included as controls. The authors concluded that a single ivermectin dose successfully improved major clinical COVID-19 manifestations, such as dyspnea, cough, and lymphopenia, without apparent adverse effects, and shortened the hospitalization length of stay. However, we found several points regarding the study design that need to be addressed.

First, the age of the study participants is a concerning issue. The mean (standard deviation) ages of patients in the ivermectin and control groups were 47.63 (22.20) years and 45.18 (23.20) years, respectively, with no significant differences between the two groups. Considering the small number of patients and the wide age range, the ages would not be normally distributed. Thus, the Mann-Whitney U test, and not the t test, should have been applied. Alternatively, the authors should have demonstrated that their data distribution was normal. Since the age of the subjects ranged from 5 to 86 years, there was a large variation in the subject populations. In general, therapeutic effectiveness of any drugs are very different among children, adults, and older individuals. Especially for COVID-19, it is well known that age greatly affects the differences of clinical presentations and prognoses; children are mostly asymptomatic, whereas middle-aged and older patients possibly manifest poor 3 symptoms with increased risk of mortality 2 . Therefore, evaluating clinical data without age stratification can cause various biases, which should be avoided.

Second, ivermectin administration timing should also be noted. As the authors stated, ivermectin potentially inhibits the nuclear transport of severe acute respiratory syndrome coronavirus 2 3 , suppressing viral replication and reducing the viral load.

Thus, the drug should be administered as early as possible 4 . However, in the study, the mean duration of symptoms before administration appeared to be approximately 6 days in both groups, which may be rather late for ivermectin administration. Moreover, the dates of treatment from disease onset varied greatly in this study, ranging from 1 to 15 days. Thus, the patients for whom ivermectin was initiated in the late phase of the disease would not benefit from the treatment. Furthermore, we wondered how the sample size of the study was calculated before starting this trial. Too much univariate analysis can lead to multiplicity concerns, and to avoid this, the authors should have recruited more patients such that multivariate analysis could be applied. In particular, the patients received various medications (lopinavir/ritonavir, chloroquine, oseltamivir, ribavirin, and antibiotics) for COIVD-19 treatment, which should have been statistically adjusted.

In light of the aforementioned concerns, in our opinion, the paper does not adequately address the efficacy of ivermectin in COVID-19 patients. Ivermectin is an inexpensive agent that can save lives in developing countries; however, a well-designed clinical trial is warranted before its clinical application.

Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

The authors declare no conflicts of interest.Dear Editor:We read with great interest the recent paper published by Shahbaznejad et al. regarding the effectiveness of ivermectin for coronavirus disease 2019 (COVID-19) 1 . In this